Software developer EDDA Technology has earned the CE mark for its IQQA-Liver product, which automates quantitative volumetric evaluation of liver, liver lobes and segments, hepatic lesions, and vasculature.
Software developer EDDA Technology has earned the CE mark for its IQQA-Liver product, which automates quantitative volumetric evaluation of liver, liver lobes and segments, hepatic lesions, and vasculature. The software facilitates evaluation of imaging data, as well as simulating tumor resection. The product, which can be deployed onto any existing hospital PACS workstations or via the web, was previously cleared by the FDA and China SFDA.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.